The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 19, 2021

Filed:

Oct. 12, 2018
Applicant:

Tapestry Pharmaceuticals, Inc., Atlanta, GA (US);

Inventors:

James D. McChesney, Etta, MS (US);

Gilles H. Tapolsky, Louisville, KY (US);

David L. Emerson, Longmont, CO (US);

John Marshall, Washington, DC (US);

Michael Kurman, Upper Saddle River, NJ (US);

Manuel Modiano, Tuscon, AZ (US);

Assignee:

TAPESTRY PHARMACEUTICALS, INC., Atlanta, GA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/357 (2006.01); A61K 31/495 (2006.01); A61K 39/395 (2006.01); A61K 31/337 (2006.01); A61K 45/06 (2006.01); C07D 493/04 (2006.01); A61K 31/4188 (2006.01);
U.S. Cl.
CPC ...
A61K 31/357 (2013.01); A61K 31/337 (2013.01); A61K 31/4188 (2013.01); A61K 31/495 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07D 493/04 (2013.01);
Abstract

Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubules at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.


Find Patent Forward Citations

Loading…